Dr. Jongmyung Kim is a Radiation Oncologist specializing in the treatment, management, and prevention of primary and metastatic lung cancers. He is an Assistant Member in the Departments of Radiation Oncology and Immunology at Moffitt Cancer Center and an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Moffitt Cancer Center is one of the top 10 cancer centers in the United States and Florida’s only National Cancer Institute-designated Comprehensive Cancer Center. It is also a co-host institute of the White House’s CancerX Moonshot Initiative. His expertise spans delivering high-quality patient care and advancing innovative theranostic strategies to overcome therapeutic resistance, with the goal of improving outcomes for patients with advanced or treatment-refractory lung cancers. Dr. Kim’s clinical approach emphasizes holistic, patient-centered care that addresses both the physical and emotional needs of his patients Dr. Kim’s career is marked by his service as a Sergeant in the 8th U.S. Army through the KATUSA (Korean Augmentation to the United States Army) program, where he was honored with U.S. Army Achievement Medals in 2003 and 2004. He earned his MD-PhD from Pusan National University School of Medicine. After completing the Medical Scientist Training Program, Dr. Kim pursued postdoctoral research on cancer stem cells at the Cleveland Clinic (Cleveland, OH), Moffitt Cancer Center (Tampa, FL), and Rutgers Cancer Institute of New Jersey (New Brunswick, NJ). He went on to complete a surgical internship at the University of Louisville (Louisville, KY), followed by a Radiation Oncology residency at Rutgers Cancer Institute of New Jersey/Rutgers Robert Wood Johnson Medical School, where he served as Chief Resident. Dr. Kim’s research focuses on developing and translating novel theranostic strategies to overcome therapeutic resistance in primary and metastatic lung cancer. He employs phage display technologies to identify and engineer tumor-specific peptides for peptide-directed immuno-radiotherapy and bispecific antibody platforms designed to enhance tumor targeting and immune modulation. In parallel, his work investigates radiation-guided immune modulation as a synergistic approach to amplify anti-tumor immunity and sensitize resistant cancers to therapy. Ultimately, Dr. Kim integrates these strategies into clinical trials aimed at overcoming therapeutic resistance and advancing patient-centered care. His research has been published in high-impact journals, including Cancer Cell, Science Translational Medicine, and Stem Cells. Dr. Kim is a member of the Education Committee of the American Society for Radiation Oncology (ASTRO) and the Scientific Review Committee at Moffitt Cancer Center. In addition to his clinical and research efforts, he is committed to mentoring future healthcare professionals and serves as Director of the Resident Radiation Biology Course. Dr. Kim’s contributions to oncology have been recognized by multiple professional societies. He is the recipient of several prestigious honors, including the 2023 American Society for Radiation Oncology (ASTRO) Recognition Award, the 2023 Korean American Society for Radiation Oncology (KASTRO) Research Grant Award, and the 2022 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Research Award.

ORCID ID

http://orcid.org/0000-0002-9625-6128

Reviewer Keywords